Page values for "Pregabalin"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Pregabalin
brand	`String`	Lyrica (IR), Lyrica CR
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Gabapentinoids\|Gabapentinoid]] • [[:Category:Anticonvulsants\|Anticonvulsant]] • [[:Category:Neuropathic pain medicines\|Neuropathic pain medicine]] • [[:Category:Schedule V controlled substances\|Schedule V controlled substance]]
mechanism	`String`
uses	`String`	'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"'
starting_dose	`String`	Neuropathic pain: 75 mg PO BID, titrate to 150 mg BID after 1 week. Fibromyalgia: 75 mg PO BID, titrate to 150 mg BID. Anxiety (off-label): 75-150 mg/day divided BID-TID
preparations	`String`	Capsules 25, 50, 75, 100, 150, 200, 225, 300 mg; oral solution 20 mg/mL; Lyrica CR tablets 82.5, 165, 330 mg
fda_max	`String`	600 mg/day (seizures); 450 mg/day (fibromyalgia and neuropathic pain)
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Neuropathic pain and fibromyalgia effect emerges over 1-2 weeks
duration	`String`	BID-TID dosing for IR; once-daily for CR
halflife	`String`	6.3 hours'"`UNIQ--ref-00000026-QINU`"'
bioavailability	`String`	≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)'"`UNIQ--ref-00000027-QINU`"'
pregnancy	`String`	Some signal for major congenital malformations; limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	'''[[USLegal:Schedule V\|Schedule V controlled substance]] in US (federally)''', distinct from gabapentin which remains federally unscheduled'"`UNIQ--ref-00000028-QINU`"'